On March 29, Shanghai Microport Endovascular Medtech (Group) Co.Ltd(688016) released the 2021 report. During the reporting period, the company achieved an operating revenue of 685 million yuan, an increase of 45.59% over the same period last year; The net profit attributable to the shareholders of the listed company was 316 million yuan, an increase of 47.17% over the same period last year; The basic earnings per share is 4.39 yuan; The company’s R & D investment totaled 123 million yuan, accounting for 18.04% of the company’s operating revenue in the same period. The company plans to distribute cash dividends of RMB 21.00 (including tax) to all shareholders for every 10 shares, and is expected to distribute RMB 151 million (including tax), accounting for 47.86% of the net profit in 2021.
The company said it would continue to keep up with the clinical market demand, continue to increase R & D investment and accelerate the improvement of product line layout. At present, among the products under development, the new generation of cratos branch aortic covered stent system has obtained the type inspection report, the new generation of aegis abdominal aortic covered stent system has obtained the animal experiment report, Fishhawk mechanical thrombectomy catheter and vena cava filter have obtained the type inspection report and animal experiment report respectively, and tips covered stent system has obtained the type inspection report. The above products are expected to gradually enter the clinical trial stage in 2022, At the same time, the company is also gradually promoting the reserve of other new technologies and R & D projects, paying close attention to the cutting-edge technologies in the industry all over the world, and continuously promoting the reserve and approval of new technologies and R & D projects.
In the future, the company will invest more human resources and funds in the field of peripheral vascular intervention, start with high-end products through independent research and development, investment and M & A, focus on the research and development of products with good market prospects and can effectively solve clinical pain points, and build a competitive product portfolio in the field of peripheral vascular as soon as possible.
Public information shows that Shanghai Microport Endovascular Medtech (Group) Co.Ltd(688016) is mainly engaged in the R & D, production and sales of medical devices for aortic and peripheral vascular intervention. In the field of aortic interventional medical devices, the company is an enterprise with a complete range of products, leading scale and market competitiveness in China. The company’s main products in this field are aortic covered stent system; In the field of peripheral vascular interventional medical devices, the company has worked deeply for many years. At present, it has peripheral drug balloon dilation catheter, peripheral vascular stent system and other products; In addition, the company has the only approved and listed intraoperative stent system that can be used in thoracic aortic dissection surgery in China. Adhering to the mission of “providing accessible true, good and beautiful medical solutions for the treatment of blood circulation diseases”, the company is committed to becoming a world leading high-tech company in the field of aortic and peripheral vascular interventional therapy.
